TABLE 2.

EKs and antifungal susceptibilities of sequential C. parapsilosis isolates from patients whose fungemia cleared on CVC removal or without CVC removal

Patient no. and Isolate no.	Date of isolation (mo/day/yr)	MICa (μg/ml)			Karyotype
		AmB	Flu	Itra
1
1-0	11/16/98	0.5	1.0	0.06	a
1-1	11/17/98	0.5	1.0	0.06	a
1-3	11/19/98	0.5	1.0	0.06	a
1-6	11/22/98	0.5	1.0	0.06	a
2
2-0	06/24/99	0.5	1.0	0.06	b
2-3	06/26/99	0.5	1.0	0.06	b
2-7	06/30/99	0.5	1.0	0.06	b
2-11	07/05/99	0.5	1.0	0.06	b
3
3-0	07/18/99	0.5	0.25	0.03	c
3-3	07/21/99	0.5	0.25	0.03	c
3-7	07/25/99	0.5	0.25	0.03	c
4
4-0	3/20/98	0.5	0.5	0.03	d
4-2	3/22/98	0.5	0.5	0.03	d
5
5-0	05/11/98	1.0	1.0	0.25	e
5-2	05/13/98	1.0	1.0	0.25	e
6
6-0	07/23/99	0.5	1.0	0.12	f
6-2	07/25/99	0.5	1.0	0.12	f
7
7-0	09/10/99	0.5	0.5	0.03	g
7-2	09/12/99	0.5	0.5	0.03	g
8
8-0	11/24/97	0.5	0.25	0.03	h
8-4	11/28/97	0.5	0.25	0.03	i
9
9-0	10/31/97	0.5	0.25	0.03	j
9-6	11/06/97	0.5	0.25	0.03	k

^aAmB, amphotericin B; Flu, fluconazole; Itra, itraconazole.